Amgen Lead Discussion on Successful Launch Strategy Under New FDAAA Guidelines /EIN News January 13th, 2009/ With FDA guidelines likely to become more stringent under the Obama administration, Pharma oncology companies are meeting to look at how to develop and execute a Risk Evaluation and Mitigation Strategy (REMS). Led by industry expert, Max Colao, Executive Director,...